Cellular immunotherapy is a promising approach to specific treatment of cancer. Dendritic cells (DC) are the beststudied antigen presenting cells (APC) and have been tested in multiple clinical trials over the last years. To extend this strategy to clinical situations in which DC therapy might be more challenging, e.g. pediatric patients or to approaches with frequent vaccinations, we have established CD40-activated B cells (CD40-B cells) as a complementary autologous APC, due to the simple generation of large amounts of highly efficient CD40-B cells from small amounts of peripheral blood. Similar to the pharmaceutical development of DC to become a standardizable adjuvant, several important biological aspects need to be addressed for CD40-B cells prior to "product development" according to GMP conditions. We have identified efficient presentation of antigen in the context of MHC class I and MHC class II as well as homing capabilities to secondary lymphoid organs as essential biological criteria for this cellular adjuvant to merit further development. Recently, we showed that antigenloaded CD40-B cells expand memory and induce primary CD8 + T cell responses in healthy donors and cancer patients alike.
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Here we address, whether CD40-B do process antigens in the context of MHC class II and induce secondary as well as primary CD4 + T-cell responses: We developed a T-cell expansion system that uses CD40-B cells as sole APC to induce antigen-specific responses of purified CD4 + T-cells: 1) tetanus toxoid (TT) and keyhole limpet hemocyanin (KLH), were used as a model for whole protein antigens, 2) the artificial promiscuous MHC class II binding peptides PADRE-AKF and PADRE-AKX served as model peptide-neoantigens. After 2 to 5 rounds of stimulation with antigen-loaded CD40-B cells ELISPOT technology was used to determine the presence of antigen specific CD4 + Tcells. While specific cells were successfully expanded for all antigens studied, INF-γ and IL-4 cytokine secretion profiles did not indicate a dominant polarization towards TH 1 or TH 2 lineage.
Similarly important, we addressed, if CD40-B cells have the potential to home to lymph nodes and induce T-cell chemotaxis: CD40-B lack receptors important for relocating to peripheral tissue but do express CD62L, LFA-1, CCR7 and CXCR4, receptors implied in homing to secondary lymphoid organs. Migration experiments using their cognate ligands CXCL12, CCL19 and CCL21 demonstrated that these receptors are fully functional and mediate migration of CD40-B cells. This article is available from: http://www.cancerci.com/content/4/S1/S49
